Endo and Jubilant Expand Oncology Discovery Partnership on Successful Delivery of Early Milestone

BANGALORE, India, January 27 - Jubilant Biosys Ltd., a subsidiary of Jubilant Organosys Ltd., and Endo
Pharmaceuticals (Nasdaq: ENDP)., of Chadds Ford, Pa., U.S.A., announced today
that they have expanded their drug discovery partnership in oncology,
following the successful delivery of an early stage milestone.

The year-old partnership focuses on Jubilant delivering preclinical
candidates in the therapeutic area of oncology. Endo owns the late-stage
development and commercialization rights for molecules discovered in the
partnership. Jubilant derives research funding and success-based development
and commercialization milestones.

Commenting on this development, Sri Mosur, CEO & President, Global Drug
Discovery & Development said: "We are pleased that we could deliver early
success to the discovery portfolio efforts at Endo Pharmaceuticals and this
expansion is a testimony to Jubilant's focus in building world class oncology
capabilities, among other therapeutic areas. This collaboration further
reinforces the concept of globally leveraged R&D that creates a platform for
scientists from Endo and Jubilant to collaborate in finding affordable
remedies for cancer patients worldwide."

"We have been impressed by the quality of the science and the
progress made to date by the Jubilant team on our ongoing oncology discovery
program, said Dr. Ivan Gergel, M.D, Executive Vice President of R&D at Endo
Pharmaceuticals. "Expanding our relationship in this important therapeutic
area is consistent with our strategy of building Endo's pipeline using a
virtual discovery approach, in conjunction with our in-licensing efforts."

About Jubilant Biosys

Jubilant Biosys Ltd. (JBL) (www.jubilantbiosys.com), a
subsidiary of Jubilant Organosys Ltd., provides integrated drug discovery and
development solutions to the global pharmaceutical industry. Jubilant Biosys
has an integrated state of the art facility in Bangalore. The Center houses
over 450 scientists specializing in multiple disciplines to include Discovery
biology, medicinal chemistry, structural biology, pharmacology, toxicology,
pharma chem, molecular modeling, crystallography and information technology
supporting discovery efforts.

About Jubilant Organosys Limited

Jubilant Organosys Ltd., headquartered at Noida, an integrated
pharmaceutical industry player, is India's largest Custom Research and
Manufacturing Services company (CRAMS) and a leading Drug Discovery and
Development Solution Provider. The company has a presence across the
pharmaceutical value chain for providing products and services such as
proprietary products, exclusive synthesis, active pharmaceutical ingredients,
contract manufacturing of sterile injectables & non-steriles products,
radiopharmaceuticals, generic dosage forms, drug discovery services,
medicinal chemistry services, clinical research services, and Health Care.
The Company also manufactures Industrial and Performance products.
www.jubl.com

Disclaimer:

Statements in this document relating to future status, events,
or circumstances, including but not limited to statements about plans and
objectives, the progress and results of research and development, potential
product characteristics and uses, product sales potential and target dates
for product launch are forward-looking statements based on estimates and the
anticipated effects of future events on current and developing circumstances.
Such statements are subject to numerous risks and uncertainties and are not
necessarily predictive of future results. Actual results may differ
materially from those anticipated in the forward-looking statements. Jubilant
Organosys may, from time to time, make additional written and oral forward
looking statements, including statements contained in the Company's filings
with the regulatory bodies and its reports to shareholders. The Company
assumes no obligation to update forward-looking statements to reflect actual
results, changed assumptions or other factors.

    For Business Queries
    Kailash Swarna
    Sr. VP and COO,
    Jubilant Drug Discovery and Development
    kailash_swarna@jubilantbiosys.com

    For Media
    Seema Ahuja
    VP-Corporate Marketing & Communications
    Jubilant Organosys Ltd
    +919810631779,
    seema_ahuja@jubl.com

For Business Queries: Kailash Swarna, Sr. VP and COO, Jubilant Drug Discovery and Development, kailash_swarna at jubilantbiosys.com; For Media: Seema Ahuja, VP-Corporate Marketing & Communications, Jubilant Organosys Ltd, +919810631779, seema_ahuja at jubl.com